论文部分内容阅读
随着对肾癌发病机制的日渐了解,小分子靶向药物如舒尼替尼和索拉非尼等已经被广泛应用于临床,显著提高了肾癌患者的生存时间。然而,约有15%的进展期肾癌患者对靶向药物先天耐药,其余患者在接受舒尼替尼治疗6~15个月后也往往出现耐药和疾病进展,成为晚期肾癌治疗的瓶颈。因此,探索肾癌靶向耐药的生物学机制以及寻找预测靶向药物疗效的生物学标记物十分迫切。我们团队近期的研究发现了在肾癌靶向药物耐药过程中起关键作用的长链非编码RNA(lncRNA),相关研究成果发表在Cancer Cell、Nature Communications和Oncogene等国际知名期刊上。本文总结了我们团队关于肾癌靶向药物耐药研究的新成果,并对未来靶向药物耐药研究的方向和难点进行了探讨。
With the growing understanding of the pathogenesis of renal cell carcinoma, small molecule targeted drugs such as sunitinib and sorafenib have been widely used in clinical and have significantly improved the survival time of patients with renal cell carcinoma. However, about 15% of patients with advanced renal cell carcinoma are congenital drug-resistant to the targeted drug, and the remaining patients often develop resistance and disease progression 6 to 15 months after sunitinib treatment and become advanced renal cancer bottleneck. Therefore, to explore the biological mechanism of targeted drug resistance of renal cell carcinoma and find biomarkers to predict the efficacy of targeted drugs is urgent. Recent research by our team has identified long-chain non-coding RNAs (lncRNAs) that play key roles in the drug resistance of kidney cancer-targeted drugs. Relevant research has been published in internationally renowned journals such as Cancer Cell, Nature Communications and Oncogene. This article summarizes the new results of our team’s research on drug-resistance of targeted cancer drugs and explores the directions and difficulties in the future of targeted drug-resistance research.